From
to ZETA
Solutions for Antibody-Drug Conjugate Manufacturing
Meet the challenges of ADC production with our expertise in containment & GMP-compliant facility design.
Antibody-drug conjugates (ADCs) offer powerful, targeted cancer therapies – but manufacturing them involves high-potency compounds and critical safety requirements.
Managing the unique challenges of ADCs. Experience drives excellence.
Containment & exposure reduction
High-containment system design (OEB5/OEB6) to safeguard personnel and environment.
High potency API handling
Safe handling and production of potent compounds.
Optimized processing
Precise control of reaction conditions for reliable conjugation.
Product protection
Controlled freezing and packaging to preserve stability throughout the supply chain.
Waste & CIP handling
Robust strategies for cleaning and safe disposal of toxic materials.
High-Tech Plant for Antibody-Drug Conjugation
Project realization in just 18 months.
ZETA delivers cutting-edge ADC downstream processing system in record time. Innovative skid-based design and precision engineering enable safe, GMP-compliant production of high-value antibody-drug conjugates in Switzerland.